Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $15.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target raised by Royal Bank Of Canada from $9.00 to $15.00 in a report published on Tuesday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

Several other equities analysts have also weighed in on the company. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday. Chardan Capital restated a “buy” rating and issued a $26.00 price target on shares of Intellia Therapeutics in a report on Friday, February 27th. Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. JonesTrading lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, William Blair raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $19.59.

Intellia Therapeutics Stock Down 4.8%

NTLA stock opened at $13.15 on Tuesday. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -3.43 and a beta of 2.10. The business has a fifty day simple moving average of $12.25 and a 200-day simple moving average of $13.10. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. During the same quarter last year, the firm earned ($1.27) earnings per share. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the transaction, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. The trade was a 9.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president owned 98,533 shares of the company’s stock, valued at $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,051 shares of company stock valued at $488,600 in the last quarter. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. Schroder Investment Management Group lifted its holdings in shares of Intellia Therapeutics by 1,593.4% in the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after purchasing an additional 382,425 shares during the last quarter. Marex Group plc acquired a new stake in Intellia Therapeutics in the second quarter worth $5,849,000. JPMorgan Chase & Co. increased its position in Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after buying an additional 396,858 shares during the period. AXQ Capital LP bought a new stake in Intellia Therapeutics in the second quarter valued at $285,000. Finally, SG Americas Securities LLC lifted its stake in Intellia Therapeutics by 239.7% in the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock valued at $2,264,000 after buying an additional 92,485 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene‑therapy trial for Intellia — a material de‑risking event that restores clinical momentum for NTLA’s in‑vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near‑term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near‑term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near‑term cost pressure acknowledged, long‑term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near‑term sentiment and give holders a reason to take profits after the run‑up. Canaccord lowers expectations

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.